Bleomycin-Electrosclerotherapy
Ok. Thank you, I'll mention BEST within the sclerotherapy voice as suggested.Orgliandino (talk) 10:26, 10 September 2021 (UTC)
Bleomycin electrosclerotherapy (short form BEST) is an experimentally practiced combination therapy of bleomycin with reversible electroporation.
Bleomycin is an active drug that is used in the treatment of cancer and as a sclerosant for vascular malformations. Bleomycin was originally discovered in Japan in the 1960s for its cytotoxic and antibiotic properties. It was later found that bleomycin also had a strong sclerosing effect. Bleomycin is one of the most commonly used sclerosants for venous and lymphatic vascular malformations.[1].
Bleomycin electrosclerotherapy consists of locally delivering the sclerosant bleomycin and applying short high voltage electrical pulses to the area to be treated, resulting in a local and temporary increased permeability of the cell membranes, increasing the intracellular concentration of bleomycin by a factor of up to several thousand[2]. Preclinical studies also indicated that electroporation in combination with bleomycin impaired the barrier function of the endothelium by interacting with the organization of the cytoskeleton and the integrity of the junctions. This can lead to extravasation, interstitial edema and a desired collapse of the vascular structures[3].
The procedure has been researched as electrochemotherapy of skin tumors since the early 1990s[4] and was first used in 2017 for vascular malformations[5]. Initial reports indicated that the use of bleomycin in combination with reversible electroporation can potentially enhance the sclerotherapy effect[6][7]. A retrospective study of 17 patients with venous malformations who did not respond to previous invasive therapies showed an average decrease in lesion volume measured on MRI images of 86 percent with clinical improvement in all patients after an average of 3.7 months and 1.12 sessions per patient, even with a reduced dose of the bleomycin and a reduced number of sessions compared to standard bleomycin sclerotherapy[8]
References
- ↑ Horbach, Sophie E. R.; Rigter, Irma M.; Smitt, J. Henk Sillevis; Reekers, Jim A.; Spuls, Phyllis I.; van der Horst, Chantal M. A. M. (2016). "Intralesional Bleomycin Injections for Vascular Malformations: A Systematic Review and Meta-Analysis". Plastic and Reconstructive Surgery. 137 (1): 244–256. doi:10.1097/PRS.0000000000001924. ISSN 1529-4242. PMID 26710030. Unknown parameter
|s2cid=ignored (help) - ↑ Jaroszeski, M. J.; Dang, V.; Pottinger, C.; Hickey, J.; Gilbert, R.; Heller, R. (2000). "Toxicity of anticancer agents mediated by electroporation in vitro". Anti-Cancer Drugs. 11 (3): 201–208. doi:10.1097/00001813-200003000-00008. ISSN 0959-4973. PMID 10831279. Unknown parameter
|s2cid=ignored (help) - ↑ Serša, Gregor; Čemažar, Maja; Markelc, Bostjan (2017), Miklavčič, Damijan, ed., "Blood Flow Modifying and Vascular-Disrupting Effects of Electroporation and Electrochemotherapy", Handbook of Electroporation, Cham: Springer International Publishing, pp. 691–705, doi:10.1007/978-3-319-32886-7_165, ISBN 978-3-319-32885-0, retrieved 2021-08-23
- ↑ Mir, L. M.; Belehradek, M.; Domenge, C.; Orlowski, S.; Poddevin, B.; Belehradek, J.; Schwaab, G.; Luboinski, B.; Paoletti, C. (1991). "[Electrochemotherapy, a new antitumor treatment: first clinical trial]". Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie. 313 (13): 613–618. ISSN 0764-4469. PMID 1723647.
- ↑ McMorrow, L.; Shaikh, M.; Kessell, G.; Muir, T. (2017). "Bleomycin electrosclerotherapy: new treatment to manage vascular malformations". British Journal of Oral and Maxillofacial Surgery. 55 (9): 977–979. doi:10.1016/j.bjoms.2017.10.002. PMID 29055573.
- ↑ Horbach, Sophie E.R.; Wolkerstorfer, Albert; Jolink, Folkert; Bloemen, Paul R.; van der Horst, Chantal M.A.M. (2020). "Electrosclerotherapy as a Novel Treatment Option for Hypertrophic Capillary Malformations: A Randomized Controlled Pilot Trial". Dermatologic Surgery. 46 (4): 491–498. doi:10.1097/DSS.0000000000002191. ISSN 1076-0512. PMID 31574025. Unknown parameter
|s2cid=ignored (help) - ↑ Dalmády, Szandra; Csoma, Zsanett; Besenyi, Zsuzsanna; Bottyán, Krisztina; Oláh, Judit; Kemény, Lajos; Kis, Erika (2020). "New Treatment Option for Capillary Lymphangioma: Bleomycin-Based Electrochemotherapy of an Infant". Pediatrics. 146 (6): e20200566. doi:10.1542/peds.2020-0566. ISSN 0031-4005. PMID 33234668 Check
|pmid=value (help). Unknown parameter|s2cid=ignored (help) - ↑ Wohlgemuth, Walter A.; Müller-Wille, Rene; Meyer, Lutz; Wildgruber, Moritz; Guntau, Moritz; Heydt, Susanne von der; Pech, Maciej; Zanasi, Alessandro; Flöther, Lilit; Brill, Richard (2021). "Bleomycin electrosclerotherapy in therapy-resistant venous malformations of the body". Journal of Vascular Surgery: Venous and Lymphatic Disorders. 9 (3): 731–739. doi:10.1016/j.jvsv.2020.09.009. PMID 33045393 Check
|pmid=value (help). Unknown parameter|s2cid=ignored (help)
External links
This article "Bleomycin-Electrosclerotherapy" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Bleomycin-Electrosclerotherapy. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
